Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year

“The modest benefits would likely not be questioned by patients, clinicians, or payers, if amyloid antibodies were low risk, inexpensive and simple to administer,” wrote UCSF’s Dr. Eric Widera, SUNY Upstate Medical University’s Dr. Sharon Brangman and the University of Wisconsin’s Dr. Nathaniel Chin. “However, they are none of these.”